# A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia

> **NCT02964936** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 100 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** roxadustat

## Key facts

- **NCT ID:** NCT02964936
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-11
- **Primary completion:** 2018-08-15
- **Final completion:** 2018-08-15
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02964936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02964936, "A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02964936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*